Patents by Inventor Masafumi Yaguchi

Masafumi Yaguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for disc herniation
    Patent number: 11944670
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: April 2, 2024
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • THERAPEUTIC AGENT FOR DISC HERNIATION
    Publication number: 20220160845
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 26, 2022
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Therapeutic agent for disc herniation
    Patent number: 11266725
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: March 8, 2022
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • THERAPEUTIC AGENT FOR DISC HERNIATION
    Publication number: 20190224289
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Therapeutic agent for disc herniation
    Patent number: 10286046
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 14, 2019
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • THERAPEUTIC AGENT FOR DISC HERNIATION
    Publication number: 20170000863
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Application
    Filed: September 8, 2016
    Publication date: January 5, 2017
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Therapeutic agent for disc herniation
    Patent number: 9463225
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: October 11, 2016
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • THERAPEUTIC AGENT FOR DISC HERNIATION
    Publication number: 20150071896
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 12, 2015
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • THERAPEUTIC AGENT FOR DISC HERNIATION
    Publication number: 20130266555
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 10, 2013
    Applicant: SEIKAGAKU CORPORATION
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi